-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
AD experts converge at AAIC
Jul 17, 2017
A year ago I wrote a blog about the great accomplishments happening in Alzheimer’s Disease (AD) research, which were highlighted at the 2016 Alzheimer’s Association International Conference (AAIC). After years of failed trials and frustrating dead ends, we have begun to see results, including advances in the understanding tau pathology and the ability to conduct tau imaging in live patients.
A year later, progress continues at a rapid clip, as we continue to expand our understanding of tauopathy, neurotoxicity of tau in the brain, and other factors in this disease.
For a long time we believed that beta amyloid plaque was the sole driver of AD symptoms, however, recent studies suggest tau protein may be the real driver, or at least an accomplice in this disease. These insights are due in part to more sophisticated tau imaging to show correlations between the spread of tau and cognitive declines. In 2016, for example, scientists from Washington University in St. Louis published results of a study showing Tau deposition in the temporal lobe more closely tracked dementia status and was a better predictor of cognitive performance than beta amyloid deposition in any region of the brain. Similarly, scientists from the University of California, Berkeley, conducted a study used the tau PET ligand AV1451 to reveal an age-related accumulation of tau in the medial temporal lobe in healthy older adults that tracks with weakening episodic memory.
These studies and the resulting knowledge open the possibility for better diagnosis and treatment of AD and other neurodegenerative diseases, including the development of anti-tau targeted therapies. Several companies are already developing tau biomarkers, and validating them in post mortem studies.
Many of these themes are currently being covered at the 2017 AAIC conference, which began July 14 and runs through the week.
AAIC 2017
Every year, AAIC brings together the world’s leading AD researchers, investigators, clinicians and the care research community to share discoveries and brainstorm new directions to take AD research. This year’s event has many presentations covering the field of amyloid and tau imaging, and discussions exploring opportunities to potentially reduce the presence of tau as a therapeutic option.
Friday’s workshops, for example, included a course on Neuroimaging in Dementia, and The Basics of Fluid Biomarkers in Alzheimer's Disease; while Sunday’s emerging concept session focused on The elimination of amyloid-beta from the brain, and how measuring the concentration of different proteins in the cerebrospinal fluid forms the basis of a CSF biomarker.
Big data and AD
Another one event I am particularly excited about is Simon Lovestone’s talk on Tuesday about The Future of Electronic Health Records and Big Data in Dementia Research.
With the recent merger between Quintiles and IMS Health, my colleagues are at the forefront of using advanced data analytics tools and access to global healthcare data to disease research. In our AD collaborations, we are mining electronic health records and other global data sources to conduct predictive analytics that help our partners select clinical trial sites, identify patient pools, and build referral networks of physicians to speed their AD trials. This is particularly important for AD research as most current trials focus on early stage patients who may be asymptomatic and thus difficult to diagnose and recruit.
QuintilesIMS is also the only CRO participating in the European Prevention of Alzheimer's Disease Consortium (EPAD), which is working to identify thousands of patients in the EU with prodromal AD and at risk for Alzheimer’s dementia, and funnel them into an adaptive trial where multiple biopharma companies can test and compare drugs in order to streamline the discovery process. The goal of the program is to deliver innovative treatment solutions to market faster and more cost effectively than ever before.
Along with attending these sessions, I look forward the many conversations I will have at AAIC with world-class researchers working to develop new diagnostic tools and treatments to fight this terrible disease. It is one of the most powerful events of the year for the AD community, and I feel privileged to be a part of it.